Strata Oncology的动态

Come speak with us at ASCO about how Strata can advance and augment your ADC development plans for both marketed and investigational ADCs!

Pharmacogenomics: Enhancing Cancer Treatment with Precision Medicine #Pharmacogenomics, the study of how genes influence an individual’s response to drugs, is transforming cancer treatment by making it more #precise and #personalized. This innovative field allows clinicians to tailor therapies based on a patient’s genetic makeup, optimizing efficacy and minimizing adverse effects. In oncology, pharmacogenomics helps identify genetic variations that influence drug metabolism, drug targets, or cancer susceptibility. For example, testing for #HER2 overexpression in breast cancer patients enables targeted therapy with trastuzumab, significantly improving outcomes. Similarly, mutations in #EGFR or #ALK genes in lung cancer patients guide the use of tyrosine kinase inhibitors, offering better survival rates compared to standard treatments. Pharmacogenomic testing also mitigates risks of severe drug toxicity. Variants in genes like DPYD can predict fluoropyrimidine sensitivity, helping adjust dosages or choose alternative treatments for colorectal or gastric cancers. As cancer research advances, integrating pharmacogenomics into clinical practice ensures therapies are not just about treating cancer—but about treating your #cancer. #Pharmacogenomics #CancerTreatment #Cancer #EGFR #HER2 #ALK #PrecisionMedicine #Oncology #Genomics

An oldie but a goodie. Tracking of the BCR-ABL fusion during the development of imatinib was a fabulous example of a successful pharmacodynamic biomarker. Imatinib, a tyrosine kinase inhibitor, was developed for treating CML, driven by the BCR-ABL fusion protein. PD biomarkers were crucial in its clinical trials to demonstrate the drug's efficacy and guide treatment strategies. The Philadelphia chromosome was tracked using two methods: 1. BCR-ABL Transcript Levels: A decrease in BCR-ABL mRNA levels by qPCR indicated effective inhibition of the BCR-ABL kinase, correlating with reduced leukemic cell proliferation. 2. Cytogenetic Response: Cytogenetic analysis of Philadelphia chromosome-positive cells. Reduction in these cells demonstrated the drug's impact on the leukemic cell population. The latter was one of the first tests I did when I started my Cytogenetics career in 2005. For those of you who have never seen what a Philadelphia chromosome looks like down the microscope- see the karyotype above! As we continue to develop more oncology therapies, remembering these milestones reinforces the power of biomarkers and their uses in our quest to conquer cancer. Don't forget to include pharmacodynamic biomarkers in your early development folks! #biomarkers #drugdevelopment #precisiononcology #biopharma ---- Hi! I'm Josie. I help Biopharma develop successful biomarker strategies. If you'd like to hear more send me a message or book a free discovery call!

Fight Cancer with Precision Medicines: Antibody Drug Conjugate (ADC) delivery of a cytotoxic drug allows greater specificity than use of the drug alone. This therapeutic modality targets cancer cells while reducing the potential impact on normal cells to improve efficacy and safety. Eurofins Discovery’s OncoPanel? and BioMAP? platforms can aid new ADC therapeutic development! OncoPanel ? Supports lead optimization with routine screening using any of our 300+ human tumor cell lines. ? Enables the identification of sensitive and resistant tumor types, along with related predictive genomic biomarkers. BioMAP ? Generates an actionable phenotypic fingerprint using the Diversity PLUS panel of 12 biological models with 148 clinically relevant protein biomarker readouts. ? Enables the identification of broader biological effects and potential toxicity signatures to help de-risk programs by comparison with 4,500+ therapeutic and reference agent profiles. Our experts can help you accelerate & de-risk your ADC program. Contact us today. https://lnkd.in/gDh2fzBP #DrugDiscovery #ADC #EurofinsDiscovery

Biomarkers like the T-cell inflamed 18-gene expression profile are linked to improved pCR and EFS in high-risk early TNBC, with or without pembrolizumab, according to KEYNOTE-522 analysis at #SABCS24. Texas Oncology https://lnkd.in/eeDhMpaK

Interested in KRAS? Tempus is presenting Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development at RAS-Targeted Drug Development Summit 2024 KRAS G12C is only the first druggable alteration in RAS genes. Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients including KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, revealing critical insights for targeted therapy development. Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes. Not attending? Let's connect! #PrecisionOncology #ClinicalDevelopment #BiomarkerStrategy #RAS #KRAS #NRAS #G12C

Spatial transcriptomics is revolutionizing cancer research. ?? This upcoming webinar details this innovative approach, which allows for the visualization and analysis of the entire transcriptome within its histological context, offering unprecedented insights into biomarker behavior and drug performance in patient-derived tumor tissues. Register now to gain insights into how the Indivumed Services platform enhances drug profiling efforts, get an overview of spatial transcriptomics, and understand its role in informing drug treatment decisions. #Transcriptomics #CancerResearch #Biomarkers

It's always amazing to see innovative, groundbreaking research in the field of cancer treatments and research. As outlined here, the "protein sandwich" technique is offering promising prospects for advancing cancer treatment modalities. Using an “intramolecular bivalent glue” researchers were able to bind together proteins that would otherwise fall apart. This has been crucial in creating more comprehensive, holistic drug development and therapeutic interventions. I’m interested to see if these new class of drugs, called “intramolecular bivalent glue,”, will be successful in creating drugs for different diseases. #CancerResearch #MedicalInnovation #ProteinTherapeutics #proteindegraders

Interesting insights on the cost-effectiveness of next-generation sequencing (NGS) panels in oncology have been revealed in a recent literature review. The study highlights that targeted panel testing could result in cost reductions compared to traditional single-gene biomarker assays. However, it also notes that larger panels with hundreds of genes may not be cost-effective. I'm sure, that, as NGS continues to grow significantly, economic evaluations of NGS testing workflows are crucial for promoting adoption and maximizing benefits for patients. Intensifying these evaluations is essential for the future of precision medicine. Read more about this thought-provoking study here: https://lnkd.in/eYwjsPPS